Global Monoclonal Antibodies Market to Reach US$ 392.6 Billion by 2032, Impelled by the Increasing Prevalence of Chronic Diseases

December 06, 2022 | Healthcare

According to the latest report by IMARC Group, titled "Monoclonal Antibodies Market Report by Production Method (In Vivo, In Vitro), Source (Murine, Chimeric, Humanized, Human), Indication (Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, and Others), End Use (Hospitals, Research Institutes, and Others), and Region 2024-2032," the global monoclonal antibodies market reached a value of US$ 221.7 Billion in 2023. Monoclonal antibodies (mAb) are produced by a single clone of cells or cell lines and consist of identical antibody molecules. These antibodies can have monovalent affinity, binding only to the same epitope. Due to their site-specificity, these serve as essential tools to detect or purify substances. They are being used on a clinical level to diagnose and treat several diseases. They are used as probes to identify materials in laboratories or home-testing kits. Due to their specificity to unique epitopes, monoclonal antibodies are widely used for diagnostic and therapeutic applications for several diseases. Several manufacturers are focusing on creating medications from many classifications to treat various disorders, including cancer and rare diseases. Monoclonal antibodies, in combination with chemotherapeutic drugs, are extensively being used to treat different malignancies.

Global Monoclonal Antibodies Market Trends:

The global market is majorly driven by the increasing prevalence of chronic diseases, such as cancer and cardiovascular diseases. In line with this, the rising demand for biologics and the growing applications of monoclonal antibodies for targeted therapies are significantly contributing to the market. This is attributed to the escalating awareness about such treatments among patients and physicians. Furthermore, various key players are undertaking strategic initiatives to develop and market mAb products. Apart from this, the heavy investments by top pharmaceutical companies in genomics research and development activities are positively influencing the market. Moreover, the increasing requirement for effective and affordable therapies for cancer treatment is catalyzing the market. Besides, an extensive product pipeline with potential effective therapies catering to a diverse range of diseases is propelling the market expansion. Additionally, the augmenting focus on the discovery and development of novel monoclonal antibody therapeutics to offer treatment for complex and severe diseases is bolstering the monoclonal antibodies market. On account of the factors above, the market is anticipated to reach a value of US$ 392.6 Billion by 2032, exhibiting a CAGR of 6.4% during 2024-2032.

Market Summary:

On the basis of the production method, the market has been segmented into in vivo and in vitro.
Based on the source, the market has been categorized into murine, chimeric, humanized, and human.
Based on the indication, the market has been classified into cancer, autoimmune diseases, inflammatory diseases, infectious diseases, and others.
Based on the end use, the market has been bifurcated into hospitals, research institutes, and others.
On the basis of the region, the market has been divided into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others) and the Middle East and Africa.
The competitive landscape of the market has been studied in the report with detailed profiles of the key players operating in the market. Some of the key players include AbbVie Inc., Amgen Inc., Biogen Inc., F. Hoffmann-La Roche AG, GSK plc, Johnson & Johnson, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A. and Thermo Fisher Scientific Inc.

Report Scope:

Report Features	Details
Base Year of the Analysis	2023
Historical Period	2018-2023
Forecast Period	2024-2032
Units	US$ Billion
Segment Coverage	Production Method, Source, Indication, End Use, Region
Region Covered	Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered	United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered	AbbVie Inc., Amgen Inc., Biogen Inc., F. Hoffmann-La Roche AG, GSK plc, Johnson & Johnson, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A. and Thermo Fisher Scientific Inc.
Customization Scope	10% Free Customization
Report Price and Purchase Option	Single User License: US$ 3899 Five User License: US$ 4899 Corporate License: US$ 5899
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
30 N Gould St, Ste
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Global Monoclonal Antibodies Market to Reach US$ 392.6 Billion by 2032, Impelled by the Increasing Prevalence of Chronic Diseases

Purchase options

Single User License ~~$3899~~ $2999
Five User License ~~$4899~~ $3999
Corporate User License ~~$5899~~ $4999

Inquire Before Buying

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.